Chao Tzu-Chieh, Lin Jen-Der, Chen Miin-Fu
Department of Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Ann Surg Oncol. 2004 Apr;11(4):407-12. doi: 10.1245/ASO.2004.06.011. Epub 2004 Mar 15.
Thyroid cancers with concurrent Graves disease are relatively rare. Accordingly, the natural history and optimal surgical treatment of thyroid cancers with Graves disease are controversial.
Sixty-one thyroid cancers with concurrent Graves disease were retrospectively reviewed. Histopathologic diagnoses included 58 papillary thyroid carcinomas (95.1%), 1 follicular carcinoma (1.6%), 1 medullary carcinoma (1.6%), and 1 Hürthle cell carcinoma (1.6%).
The sample included 54 females and seven males. Subjects' ages ranged from 20 to 73 years (mean +/- SD, 35.9 +/- 10.6 years; median, 37 years). Average tumor size was 10.7 +/- 15.9 mm (range, 1-70 mm). Forty-nine tumors (80.3%) were 10 mm or smaller. Surgical procedures included subtotal thyroidectomy (40 patients), total thyroidectomy (16 patients), total thyroidectomy plus neck dissection (2 patients), near-total thyroidectomy (1 patient), and lobectomy with contralateral subtotal lobectomy (1 patient). Thirty-seven patients (60.7%) underwent postoperative 131I ablation for thyroid remnant. Neck lymph node metastases occurred in three patients and lung metastases in two patients. Patients who developed metastases were younger and had significantly larger tumors and higher pretreatment serum T3 level than those who did not develop metastases. No deaths occurred during the 6.2 +/- 4.1 year follow-up period (range, 1 year and 2 months to 18 years and 11 months).
Most thyroid cancers with concurrent Graves disease were 10 mm or smaller. Subtotal thyroidectomy is adequate for patients with Graves disease with concurrent carcinoma 10 mm or smaller.
合并格雷夫斯病的甲状腺癌相对罕见。因此,合并格雷夫斯病的甲状腺癌的自然病史和最佳手术治疗存在争议。
回顾性分析61例合并格雷夫斯病的甲状腺癌患者。组织病理学诊断包括58例乳头状甲状腺癌(95.1%)、1例滤泡癌(1.6%)、1例髓样癌(1.6%)和1例许特莱细胞癌(1.6%)。
样本包括54名女性和7名男性。受试者年龄范围为20至73岁(平均±标准差,35.9±10.6岁;中位数,37岁)。平均肿瘤大小为10.7±15.9毫米(范围,1至70毫米)。49个肿瘤(80.3%)直径为10毫米或更小。手术方式包括甲状腺次全切除术(40例患者)、甲状腺全切除术(16例患者)、甲状腺全切除术加颈部淋巴结清扫术(2例患者)、近全甲状腺切除术(1例患者)和患侧甲状腺叶切除术加对侧甲状腺次全切除术(1例患者)。37例患者(60.7%)术后接受了131I甲状腺残留消融治疗。3例患者发生颈部淋巴结转移,2例患者发生肺转移。发生转移的患者比未发生转移的患者更年轻,肿瘤明显更大,治疗前血清T3水平更高。在6.2±4.1年的随访期内(范围,1年2个月至18年11个月)无死亡病例。
大多数合并格雷夫斯病的甲状腺癌直径为10毫米或更小。对于合并直径10毫米或更小癌灶的格雷夫斯病患者,甲状腺次全切除术是足够的。